Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B-cell Lymphoma
Clinical trial register · China

Diffuse Large B-cell Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Guangzhou 14 Shanghai 14 Fuzhou 7 Changchun 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Ruijin Hospital5 Fudan University4 Hoffmann-La Roche3 Genmab3 Institute of Hematology & Blood Diseases Hospital, China2
Site location
Beijing21 Guangzhou14 Shanghai14 Fuzhou7 Changchun7
All 48 locations
Target enrolment
to

Diffuse Large B-cell Lymphoma trials in China

54 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The First Hospital of Jilin University
Phase 4
26
Changchun
2026-10-15
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
282
Beijing
2026-10-08
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
204
Guangzhou, Suzhou
2026-09
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsPenpulimab·Cytarabine·Methotrexate·Rituximab
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Rong Tao
Phase 2
69
Shanghai
2026-06-16
Recruiting
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Not yet open
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07159906Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsHomoharringtonine·Lisaftoclax·Prednisone·Rituximab
First Affiliated Hospital of Zhejiang University
Phase 1/2
62
Hangzhou
2025-09-08
Recruiting
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
Shanghai Zhongshan Hospital
Phase 2
38
Shanghai
2025-06-20
Recruiting
Fudan University
Observational
300
Shanghai
2025-05-09
Recruiting
Fudan University
Phase 2
130
Shanghai
2025-05-08
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
282
Beijing, Guangzhou
2025-04-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Ma’anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
Ruijin Hospital
Phase 2
152
Shanghai
2025-04-01
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06830031Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
Shanghai Exuma Biotechnology Ltd.
Phase 1
18
Tianjin
2025-03-25
Recruiting
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
NCT07188077Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Ting YANG
Observational
20
Fuzhou
2025-03-01
Recruiting
Ting YANG
Observational
10
Fuzhou
2025-03-01
Recruiting
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
NCT06764017Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Ningbo University
Phase 2
30
Ningbo
2025-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Recruiting
First Affiliated Hospital of Ningbo University
Phase 2
50
Ningbo
2025-01-15
Recruiting
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2024-11-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
22
Xiamen
2024-10-21
Recruiting
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411Diffuse Large B-cell Lymphoma
Navy General Hospital, Beijing
Phase 2
80
Beijing
2024-09-24
Recruiting
Navy General Hospital, Beijing
Phase 2
240
Beijing
2024-08-30
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Ruijin Hospital
Phase 3
100
Shanghai
2024-07-29
Recruiting
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Recruiting
Fudan University
Phase 1
9
Shanghai
2024-07-18
Recruiting
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
NCT06213636Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell, Diffuse Large B Cell Lymphoma
Essen Biotech
Phase 1/2
75
Beijing
2024-07-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
108
Tianjin
2024-05-30
Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
NCT06244368Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
115
Tianjin
2024-01-17
Recruiting
He Huang
Early Phase 1
18
Hangzhou
2023-11-16
Recruiting
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT06176729Diffuse Large B Cell Lymphoma
Yan Zhang, MD
Phase 2
30
Beijing
2023-10-24
Active, closed
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
Frontline of ASCT in High-risk DLBCL
NCT05831865Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Observational
175
Beijing
2023-05-03
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Active, closed
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Recruiting
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Recruiting
Huazhong University of Science and Technology
Phase 2
41
Wuhan
2022-11-26
Active, closed
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Fudan University
Phase 2
83
Shanghai, Ürümqi
2022-02-26
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
NCT06081478B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-01-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Recruiting
Ruijin Hospital
Phase 3
640
Shanghai
2021-09-17
Recruiting
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
NCT05040555Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
oubai, MD/PhD
Not applicable
64
Changchun
2021-08-30
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
Ruijin Hospital
Phase 2
40
Shanghai
2020-08-26
By invitation
Chinese Academy of Medical Sciences
Observational
407
Beijing
2020-07
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies listing the condition Diffuse Large B-cell Lymphoma.

How many Diffuse Large B-cell Lymphoma trials are recruiting in China?

40 of the 54 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 10 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B-cell Lymphoma), 54 studies
PhaseStudiesRecruitingShare
Phase 2161529.6%
Phase 310418.5%
Observational8614.8%
Phase 1/28514.8%
Phase 1549.3%
Not applicable437.4%
Early Phase 1111.9%
Phase 2/3111.9%
Phase 4111.9%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B-cell Lymphoma)
Lead sponsorStudiesRecruiting
Ruijin Hospital54
Fudan University44
Genmab30
Hoffmann-La Roche31
First Affiliated Hospital of Ningbo University22
Institute of Hematology & Blood Diseases Hospital, China22
Merck Sharp & Dohme LLC22
Navy General Hospital, Beijing22
Sichuan Baili Pharmaceutical Co., Ltd.20
Sun Yat-sen University22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.